E FOR L AIM PUBLIC COMPANY LIMITEDSET: EFORL🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

In 2025, domestic demand for medical devices continued to grow. This was partly driven by the recurring outbreaks of monitored diseases, including COVID-19, as well as health impacts related to air pollution.

For 2026 and 2027, demand for medical devices is expected to grow at a level comparable to 2025 or slightly improve, supported by several structural factors, including Thailand’s transition to an aging society, the rising number of patients with non-communicable diseases (NCDs), the expansion of the medical tourism market driven by global health awareness, and government policies promoting domestic medical device manufacturing.

In this industry environment, the Company and its subsidiaries reported total revenue of Baht 1,305.57 million for the year ended 31 December 2025, representing a decrease of Baht 34.44 million, or 3%, compared to the previous year.

Nevertheless, despite the decline in revenue, the Group’s operating performance improved compared to the prior year. Net profit for 2025 amounted to Baht 44.57 million, representing an increase of 126% year-on-year. The improvement was primarily attributable to a higher gross profit margin, effective cost management, and lower finance costs.

In addition, the Group reported total comprehensive income of Baht 38.95 million for 2025, an increase of 98% compared to the previous year, reflecting the overall improvement in the Group’s performance.

Operating Results & Financial Condition

Operating Results & Profitability

Revenues from sales and services

For the year ended 2025, revenue from sales and services of the Company and its subsidiaries was THB 1,305.57 million, representing a decrease of 3% compared to the same period last year (YE2024: THB 1,340.01 million).

  • Revenue from sales from medical equipment for the year end 2025 amounted to THB 1,267.46 million, a decrease of THB 43.83 million or 3% from THB 1,311.29 million in FY2024.

  • Revenue from services was mainly derived from maintenance services under maintenance contracts provided to customers both during and after the warranty period, as well as from rental services of medical instruments and equipment. Service revenue for the year ended 31 December 2025 amounted to THB 38.11 million, representing an increase of THB 9.40 million or 33% compared to the same period of the previous year (YE2024: 28.71 million).

Cost of Sales and Services and Gross Profit

  • The cost of sales for medical devices and equipment includes the cost of goods, transportation fees, and import duties.

  • The cost of services comprises consumable materials, repair costs, employee-related expenses, product testing costs, and other related expenses.

For the year ending 2025, the total cost of sales and services amounted to THB 848.21 million, a decrease of THB 43.57 million or 5% from the previous year (YE2024: THB 448.23 million. The decrease was in line with the decline in revenue, with a slightly higher rate of reduction.

As a result, the Group’s gross profit was THB 457.36 million, an increase of 2% compared to the same period last year (YE2024: THB 891.78 million). The gross profit margin ratio in YE2025 was 35 %, increasing by 1.6% points from the previous year.

Selling and Administrative Expenses

Selling and administrative expenses in YE2025 amounted to THB 389.68 million, consisting of selling expenses of THB 255.64 million (a decrease of 4%) and administrative expenses of THB 134.04 million (a decrease of 2%) compared to the same period last year.

Financial costs

In YE2025, financial costs amounted to THB 27.86 million, a decrease of 16% compared to the same period last year, due to increased borrowing from other parties during the year.

Net income/Loss

For the year ended 31 December 2025, the Company and its subsidiaries reported a net profit of THB 44.57 million, representing an increase of 126% compared to the same period of the previous year. The increase was mainly due to a higher gross profit margin, expense management, and lower finance costs.

Total comprehensive income for the year amounted to THB 38.95 million, an increase of 98% compared to the same period last year. During the year, the Group recognized actuarial loss relating to employee benefit obligations.

Other Analysis

TitleDescription
Financial position

Total Assets

As of 31 December 2025, the Company and its subsidiaries reported total assets of THB 1,252.88 million, representing a decrease of THB 153.21 million, or 11%, compared to the end of 2024. The decrease was primarily attributable to a reduction in cash and cash equivalents, as well as trade receivables, as the Company utilized cash flows during the year to repay outstanding liabilities. Key financial data is presented as follows:

  • The trade accounts receivable: As of 31 December 2025, the Group’s trade receivables totaled THB 326.60 million, representing a decrease of THB 91.91 million, or 22%, compared to the previous year. The decline was in line with the decrease in sales during the year.

    The majority of the Company’s customers are public healthcare institutions. By nature, government entities generally carry lower credit risk than private sector customers, as their payments are supported by allocated annual budgets. However, disbursement procedures of government agencies must comply with official regulations and administrative processes, which typically result in longer collection periods. Accordingly, trade receivables outstanding for more than 12 months in the medical device business are considered a normal industry practice.

  • Inventories: As of 31 December 2025, inventories totaled THB 399.74 million, increasing by THB 32.69 million, or 9%, from the previous year. The increase was mainly attributable to higher inventory purchases in preparation for scheduled deliveries and expected customer demand.

  • Restricted depostis with bank: As of 31 December 2025, restricted deposits totaled THB 75.99 million (including both current and non-current portions), representing deposits pledged as collateral for credit facilities with financial institutions.Restricted deposits decreased from the end of 2024 because, in 2024, such deposits included amounts placed with the Legal Execution Department in connection with a share purchase dispute. The Company subsequently won the case and received a partial refund, with the remaining balance of THB 2.45 million separately presented as “Amount due from the Legal Execution Department.”

  • Property, plant and equipment: As of 31 December 2025, property, plant and equipment amounted to THB 325.82 million, primarily consisting of land and buildings of THB 237.27 million and medical equipment and instruments of THB 85.93 million. The land and buildings have been mortgaged as collateral for credit facilities with a financial institution.

Total liabilities

As of 31 December 2025, the Company and its subsidiaries reported total liabilities of THB 669.63 million, representing a decrease of THB 192.16 million, or 22%, compared to the end of 2024. The decrease was mainly driven by repayments of trade payables and borrowings during the year, which led to a lower overall debt position at year-end.

  • Short-term loans from other parties: The Group obtained short-term loans from other parties due to credit facility limitations imposed by financial institutions for inventory purchases. As of 31 December 2025, short-term borrowings from other parties amounted to THB 58.00 million, bearing interest at rates ranging from 12% to 14% per annum. Certain portions of these borrowings are guaranteed by third parties, with a guarantee fee of 2.00% per annum.

  • Trade accounts payable - general suppliers: As of 31 December 2025, trade payables to general suppliers amounted to THB 205.24 million, decreasing by THB 87.60 million, or 30%, from the end of 2024. The decrease was mainly due to the Company’s settlement of outstanding balances in late 2025.

  • Other current payables - related parties: Other payables represent liabilities arising from the rental of medical equipment and instruments, as well as import service fees. As of 31 December 2025, other payables amounted to THB 24.99 million, representing a decrease of 39% from the end of the previous year. The decrease was primarily due to partial repayments made during the year.

  • Short-term loans and accrued interest expenses - related parties: As of 31 December 2025, short-term borrowings and accrued interest from related individuals and companies totaled THB 34.58 million, comprising principal of THB 30.00 million and accrued interest of THB 4.58 million. These borrowings represent short-term loans from a director in the form of promissory notes, bearing interest at rates of 5.00%–6.00% per annum, repayable on demand, and unsecured.

  • Loans from a related person (a relative of a director): As at 31 December 2025, loan from a related person totaled THB 44.85 million, presented in the financial statements as follows:

- THB 11.96 million under current liabilities "Current portion of long-term loans from related person" and

- THB 32.89 million as "Long-term loans from related person".

Loan from a related person was initially incurred in 2021 for THB 83.75 million, with no collateral, and bears interest at MLR - 0.25% per annum. The Company is scheduled to repay the principal and interest in 84 installments of THB 1.00 million each. The remaining principal amount and interest will be fully repaid by 25 September 2028. The Company entered into two amendments to the loan agreement to defer the repayment, during which only interest payments were made to the lender, as follows:

- On 26 April 2023 – Principal repayment was deferred for the installments from May to December 2023 (8 installments).

- On 2 February 2024 – Second amendment to defer principal repayment from January to August 2024 (8 installments). The remaining outstanding balance will be fully repaid by 2028.

  • Long term loans from shareholders and other parties: As at 31 December 2025, loans from shareholders and other parties totaled THB 143.58 million, presented in the financial statements in two portions as follows:

- THB 46.80 million under current liabilities "Current portion of long-term loans from shareholders and other parties" and

- THB 96.78 million under "Long-term loans from shareholders and other parties"

During 2021, the Company entered into loan agreements with four individuals and a related party, totaling Baht 335 million, to restructure debts at an interest rate of MLR-0.25% per annum. The principal and interest are repayable in 84 installments of Baht 3.98 million each, with the remaining balance settled in the final installment by 25 September 2028.

The objective of these loans was to restructure the Company's debt, enabling repayment to a financial institution before the maturity date and reducing the interest burden. Additionally, the interest rate received is lower than that from banks, reducing the Company's commitment to its main bank and enabling it to seek funding from other sources in the future, thereby enhancing the Company's opportunities. The Company has changed the repayment conditions for long-term loans from a shareholder and other parties as follows:

- 26 April 2023 Defer the repayment of the principal amount from May 2023 to December 2023.

- 2 February 2024 Defer the repayment of the principal amount from January 2024 to August 2024.

- 30 September 2024 Repay only interest from September 2024 to January 2025 and repay principal amount (as newly agreed) with interest from February 2025 to December 2028.

Shareholders' Equity

• As at 31 December 2025, the Company and its subsidiaries had shareholders' equity of THB 583.26 million, an increase of THB 38.95 million, or 7 percent, from THB 544.31 million at the end of 2024. This was mainly due to improved operating performance in 2025.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

1. External Factors

1.1 Economic and Social Trends

  • Thailand's transition into an aging society is driving a continuous increase in demand for medical services and equipment.

  • Growing consumer awareness of health is contributing to the expansion of the medical equipment market.

  • The rise of medical tourism is prompting hospitals and healthcare centers to invest in advanced medical technology to accommodate both domestic and international patients.

However, economic volatility may affect the purchasing power of the private sector and government budget allocations, which may impact investment decisions in certain medical equipment.

1.2 Government Policies and Regulations

  • The Ministry of Public Health's initiative to promote the adoption of Electronic Medical Records (EMR) presents an opportunity for the Company to expand its market in medical software and equipment.

Changes in government procurement regulations or policies may affect the timeline and conditions for the sale of medical equipment.

1.3 Technology and Innovation

  • The increasing use of artificial intelligence (AI) and automation in the healthcare industry enhances opportunities for developing software solutions, such as patient data analytics and decision-support systems for medical professionals.

2. Internal Factors

2.1 Market Expansion Strategy and Innovation

  • The Company prioritizes the development of medical software, both proprietary solutions and imported technologies, to enhance its product offerings.

2.2 Impact of Legal Proceedings

  • A legal dispute related to the sale of a subsidiary’s shares in 2017 previously posed financial risks to the Company. However, a Supreme Court ruling on February 24, 2025, dismissed the plaintiff’s claims, relieving the Company of any repayment obligations. This outcome reduces financial risk and strengthens investor confidence.

Considering the aforementioned factors, the Company has significant growth opportunities driven by the rising demand for medical equipment and supportive government policies. Furthermore, advancements in software technology and artificial intelligence will strengthen the Company's competitive position. Nevertheless, to ensure business stability and achieve sustainable returns for shareholders, the Company must carefully manage risks related to economic conditions, political developments, and long-term trends in the healthcare market.

Contents